Arcus Biosciences annual diluted eps
Diluted EPSBasic EPS
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Arcus Biosciences EPS History: Annual & Quarterly (RCUS)
Arcus Biosciences's diluted EPS was -$3.29 for fiscal 2025.
View full Arcus Biosciences company overviewArcus Biosciences annual diluted eps history
| Fiscal year | Period ended | Diluted EPS | Basic EPS | Change | Growth |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | -$3.29 | -$3.29 | -$0.15 | — |
| 2024 | 2024-12-31 | -$3.14 | -$3.14 | $1.01 | — |
| 2023 | 2023-12-31 | -$4.15 | -$4.15 | -$0.44 | — |
| 2022 | 2022-12-31 | -$3.71 | -$3.71 | -$4.42 | — |
| 2021 | 2021-12-31 | $0.71 | $0.76 | $2.95 | — |
| 2020 | 2020-12-31 | -$2.24 | -$2.24 | -$0.31 | — |
| 2019 | 2019-12-31 | -$1.93 | -$1.93 | -$0.50 | — |
| 2018 | 2018-12-31 | -$1.43 | -$1.43 | $27.60 | — |
| 2017 | 2017-12-31 | -$29.03 | -$29.03 | -$8.23 | — |
| 2016 | 2016-12-31 | -$20.80 | -$20.80 | — | — |
Arcus Biosciences quarterly diluted eps
Diluted EPSBasic EPS
Q1.17
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Diluted EPS | Basic EPS | Change | YoY change |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | -$0.72 | -$0.72 | -$0.72 | — |
| Q1 2026 | 2026-03-31 | -$1.02 | -$1.02 | $0.12 | — |
| Q4 2025 | 2025-12-31 | -$0.89 | -$0.89 | — | — |
| Q3 2025 | 2025-09-30 | -$1.27 | -$1.27 | -$0.27 | — |
| Q2 2025 | 2025-06-30 | $0.00 | $0.00 | $1.02 | — |
| Q1 2025 | 2025-03-31 | -$1.14 | -$1.14 | -$1.09 | — |
| Q3 2024 | 2024-09-30 | -$1.00 | -$1.00 | -$0.06 | — |
| Q2 2024 | 2024-06-30 | -$1.02 | -$1.02 | $0.02 | — |
| Q1 2024 | 2024-03-31 | -$0.05 | -$0.05 | $1.04 | — |
| Q3 2023 | 2023-09-30 | -$0.94 | -$0.94 | -$0.04 | — |
| Q2 2023 | 2023-06-30 | -$1.04 | -$1.04 | -$0.11 | — |
| Q1 2023 | 2023-03-31 | -$1.09 | -$1.09 | -$0.13 | — |
| Q3 2022 | 2022-09-30 | -$0.90 | -$0.90 | $0.21 | — |
| Q2 2022 | 2022-06-30 | -$0.93 | -$0.93 | $0.16 | — |
| Q1 2022 | 2022-03-31 | -$0.96 | -$0.96 | $0.12 | — |
| Q3 2021 | 2021-09-30 | -$1.11 | -$1.11 | -$1.14 | — |
| Q2 2021 | 2021-06-30 | -$1.09 | -$1.09 | -$0.16 | — |
| Q1 2021 | 2021-03-31 | -$1.08 | -$1.08 | -$0.45 | — |
| Q3 2020 | 2020-09-30 | $0.03 | $0.03 | $0.54 | — |
| Q2 2020 | 2020-06-30 | -$0.93 | -$0.93 | -$0.29 | — |
| Q1 2020 | 2020-03-31 | -$0.63 | -$0.63 | -$0.22 | — |
| Q3 2019 | 2019-09-30 | -$0.51 | -$0.51 | -$0.26 | — |
| Q2 2019 | 2019-06-30 | -$0.64 | -$0.64 | -$0.32 | — |
| Q1 2019 | 2019-03-31 | -$0.41 | -$0.41 | $0.96 | — |
| Q3 2018 | 2018-09-30 | -$0.25 | -$0.25 | $11.61 | — |
| Q2 2018 | 2018-06-30 | -$0.32 | -$0.32 | $5.32 | — |
| Q1 2018 | 2018-03-31 | -$1.37 | -$1.37 | $3.59 | — |
| Q3 2017 | 2017-09-30 | -$11.86 | -$11.86 | — | — |
| Q2 2017 | 2017-06-30 | -$5.64 | -$5.64 | — | — |
| Q1 2017 | 2017-03-31 | -$4.96 | -$4.96 | — | — |
Arcus Biosciences diluted eps trends
Over the last five fiscal years, Arcus Biosciences's diluted eps decreased from -$2.24 to -$3.29, a change of -$1.05. The latest reported quarter, Q2 2026, shows -$0.72.
About the metric
What earnings per share (EPS) means
Earnings per share (EPS) shows how much profit or loss is attributable to each common share. Diluted EPS includes the potential effect of convertible securities, options, and other instruments that could increase the share count, while basic EPS uses the weighted-average common shares actually outstanding.
Calculation and source
SEC-reported diluted and basic EPS
TickerStat displays diluted and basic earnings per share from SEC filings. Historical EPS values are adjusted to the current share basis when SEC-reported stock-split conversion ratios are available; they are not analyst estimates or earnings forecasts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcus Biosciences source filings ↗Community posts
Arcus sets $17.50 share price for $250 million equity financing
Arcus Biosciences ($RCUS) priced an underwritten public offering of 14,285,715 new common shares at $17.50 apiece, targeting approximately $250 million in gross proceeds. The company is selling all of the shares, so the financing would add ...
Arcus reports additional kidney-cancer data supporting casdatifan development
Arcus Biosciences ($RCUS) released additional results from the ARC-20 program evaluating casdatifan in kidney cancer. Across pooled monotherapy cohorts involving 121 heavily pretreated patients, median overall survival was 35 months, median ...
